Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did it with enough swagger to make even 2021’s unicorns blush.

A cautiously exuberant deal boom

• Venture funding for therapeutics and discovery platforms ended 2025 at a respectable $7.0 billion in Q4, matching Q4 2024, but the full-year haul slipped, a reminder that not every pipeline gets a participation trophy anymore.
• Instead, 2025’s real action came from partnerships: more than $250 billion in biopharma licensing value through Q4, the highest since 2016, with upfronts holding steady at about 7% of headline deal totals, suggesting lawyers, not froth, did most of the heavy lifting.
• M&A added emphasis rather than subtlety, with 129 deals totaling roughly $138 billion and nine transactions clearing the $5 billion mark, including fresh Q4 announcements from Novartis, Merck and Novo Nordisk that confirmed bargain-hunting is now a core therapeutic area.

Venture capital grows up (a little)

• The check-writers did not disappear; they just raised their standards, funneling capital toward later-stage companies with clinical data and near-term commercial prospects, while early-stage seed and Series A deals lost momentum into Q4.
• More than 80 venture rounds topped $100 million in 2025, a figure that sounds frothy until one remembers it is now the price of admission for programs seen as genuinely “de-risked,” a term that now means “fewer ways to blow up” rather than “no way to blow up.”
• Median round sizes climbed especially for Phase II companies, reaching about $60 million in 2025, as investors opted to finance fewer stories but insisted on thicker plot lines and clearer endings.

Licensing replaces the IPO roadshow

• If 2021 was the year every platform wanted a ticker, 2025 was the year they settled for a term sheet: licensing deals reached roughly $250.2 billion across 516 transactions, with the real upside packed into milestones rather than the opening number.
• Big pharma leaned into late-stage in-licensing, paying sharply higher upfronts for Phase III assets and stepping up payments for select preclinical programs to secure options on tomorrow’s blockbusters before rivals finished their KOL webinars.
• Oncology set the pace, with Phase II programs seeing median upfronts around $150 million and Phase III assets clearing the $1 billion upfront hurdle, a reminder that while cancer remains hard, paying up for differentiated data remains remarkably easy.

Obesity, China and the new power brokers

• Obesity and diabetes partnerships hit record heights in 2025, as GLP‑1 and GIP programs attracted nine-figure upfronts and multi-billion-dollar headline values, turning metabolic disease into the sector’s closest thing to a macro trade.
• Chinese biopharma cemented its status as a crucial innovation supplier, with a rising share of global big pharma deals featuring at least $50 million upfront going to China-based partners, underscoring that geographic risk can be negotiated, but clinical differentiation cannot.
• Biologics, particularly antibody-drug conjugates, dominated both early-stage venture funding and licensing upfronts, while small molecules quietly held the number-two slot, the dependable workhorse in a market increasingly obsessed with engineered complexity.

The IPO window: technically open, spiritually closed

• Only nine biopharma IPOs raised about $1.6 billion on U.S. exchanges in 2025, making it one of the leanest listing years in more than a decade and turning the traditional “roadshow” into something closer to a limited-release art film.
• Companies that did slip through were typically later-stage and modestly sized, signaling that public investors are still wary of paying upfront for preclinical promises when they can buy milestone‑laden exposure through better-capitalized partners.
• For now, the industry’s capital stack reads like a polite but firm note from the market: come back with data, a partner, or a term sheet—and preferably all three—then we can talk about ringing bells again.

The Sources

[1] Q4 2025 Biopharma Licensing and Venture Report https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q4-2025.pdf